Is there a role for anti-IgE in combination with specific allergen immunotherapy?

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 6, 2003, Pages 501-510

  Hamelmann, Eckard ^a,b   Rolinck Werninghaus, Claudia ^a   Wahn, Ulrich ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Allergen specific immune therapy; Anti IgE therapy; Antiallergic treatment

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHROMONE DERIVATIVE; CORTICOSTEROID; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; INSECT VENOM; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LEUKOTRIENE; OMALIZUMAB; PLACEBO; PROSTAGLANDIN; ANTI-IGE; ANTIIDIOTYPIC ANTIBODY;

ALLERGIC RHINITIS; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ASTHMA; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRUG UTILIZATION; FOOD ALLERGY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAST CELL DEGRANULATION; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; TECHNIQUE; CHEMISTRY; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; METHODOLOGY; RHINITIS;

ANTIBODIES, ANTI-IDIOTYPIC; ASTHMA; CLINICAL TRIALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; RHINITIS;

EID: 1842527234     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200312000-00013     Document Type: Review

References (58)

1. Johansson S, Hourihane J, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56:813-824.
2. Anonymous. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12:315-335.
3. Beasley R, Crane J, Lai C, Pearce N. Prevalence and etiology of asthma. J Allergy Clin Immunol 2000; 105:S466-S472.
4. Mitchell E. Asthma epidemiology: clues and puzzles. Pediatr Pulmonol 1999; 18 (Suppl):31-33.
5. British Thoracic Society. British guideline on the management of asthma. Thorax 2003; 58 (Suppl 1):i1-94.
6. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol 2002; 110:S141-S219.
7. Fick R, Fox J, Jardieu P. Immunotherapy approach to allergic disease. Immunopharmacology 2000; 48:307-310.
8. Bryan S, Leckie M, Hansel T, Barnes P. Novel therapy for asthma. Expert Opin Investig Drugs 2000; 9:25-42.
9. Barnes P. Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol 2000; 123:196-204.
10. Busse W, Rosenwasser L. Mechanisms of asthma. J Allergy Clin Immunol 2003; 111:S799-S804. Recent review illustrating the immunologic mechanisms of asthma.
11. Hamelmann E, Gelfand E. IL-5-induced airway eosinophilia: the key to asthma? Immunol Rev 2001; 179:182-191.
12. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269:68-73.
13. Saban R, Haak-Frendscho M, Zine M, et al. Human Fc ERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 1994; 94:836-843.
14. Presta L, Lahr S, Shields R, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151:2623-2632.
15. Leung D, Sampson H, Yunginger J, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986-993. First publication of a protective effect of treatment with anti-IgE (TNX-901) on food allergen-induced allergic symptoms in patients with severe peanut allergy.
16. Hamelmann E, Rolinck-Werninghaus C, Wahn U. From IgE to anti-IgE: where do we stand? Allergy 2002; 57:983-994. Recent overview of the published data on in-vitro and clinical data on anti-IgE therapy.
17. Fox J, Hotaling T, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996; 279:1000-1008.
18. MacGlashan D, Bochner B, Adelman D, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438-1445.
19. Fick R. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulm Med 1999; 5:76-80.
20. Jardieu P, Fick R. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999; 118:112-115.
21. Casale T, Bernstein L, Busse W, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-121.
22. Fahy J, Cockroft D, Boulet L, et al. Effect of aerolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160:1023-1027.
23. Boulet L, Chapman K, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155:1835-1840.
24. Fahy J, Fleming H, Wong H, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828-1834.
25. Milgrom H, Fick R, Su J, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999; 341:1966-1973.
26. Busse W, Corren J, Lanier B, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
27. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:154-161.
28. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:e36.
29. Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20:1088-1094.
30. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111:278-284. Data demonstrating the benefit of add-on anti-IgE (omalizumab) treatment on QOL in severe allergic asthma.
31. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111:87-90. Compilation of three multicenter studies with anti-IgE (omalizumab) in patients with steroid-dependent asthma demonstrating reduction in serious exacerbations with need of unscheduled/emergency treatment.
32. Malling H. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53:461-472.
33. Juniper E, Guyatt G, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93:413-423.
34. Malone D, Lawson K, Smith D, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99:22-27.
35. Ädelroth E, Rak MS, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253-259.
36. Casale T, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis. JAMA 2001; 286:2956-2967.
37. Plewako H, Arvidsson M, Petruson K, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110:68-71. Investigation of effects of anti-IgE (omalizumab) on local cellular inflammation in SAR.
38. Frew A. Immunotherapy of allergic disease. J Allergy Clin Immunol 2003; 111:S712-S719. Comprehensive review on the immunologic background and significance of SIT in allergic disease.
39. Durham S, Ying S, Varney V, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T-lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing mRNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-1365.
40. Ebner C, Siemann U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Phl p1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007-1015.
41. Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001; 126:97-101.
42. Bousquet J, Lockey R, Malling H-J, the WHO panel members. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO Position Paper. J Allergy Clin Immunol 1998; 102:558-562.
43. Abramson M, Puy R, Weiner J. Allergen immunotherapy for asthma [Cochrane review]. In: The Cochrane Library, issue 3. Oxford: Update Software; 2003. Systematic Cochrane metaanalysis of the efficacy of immunotherapy in asthma.
44. Creticos P, Reed C, Norman P, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334:501-506.
45. American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology: Joint Task Force on Practice Parameters. Allergen immunotherapy: a practice parameter. Ann Allergy Asthma Immunol 2003; 90:1-40. Recent comprehensive guidelines for the use of SIT.
46. Varney V, Gaga M, Frew A, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302:265-269.
47. Varney V, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double blind placebo controlled trial. Clin Exp Allergy 1997; 27:860-867.
48. Durham S, Walker S, Varga E-M, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-475.
49. Eng P, Reinhold M, Gnehm H. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57:306-312. First study to demonstrate persisting effect of SIT in children with SAR.
50. Pajno G, Barbiero G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397.
51. Möller C, Dreborg S, Ferdousi H, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 2002; 109:251-256. Multicenter study showing that SIT in children is associated with a reduced incidence of new sensitizations and development of asthma in children with allergic rhinitis.
52. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:274-280. First study investigating the additive effect and demonstrating a superior efficacy of the combined treatment with SIT and anti-IgE (omalizumab) in children and adolescents with seasonal allergic rhinitis.
53. Kopp M, Brauburger J, Riedinger F, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 110:728-735. In-vitro analysis of the efficacy of combination therapy with SIT and anti-IgE (omalizumab) to reduce leukotriene release.
54. Platts-Mills T. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164:S1-S5.
55. Hamelmann E, Takeda K, Schwarze J, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol 1999; 21:480-489.
56. Oettgen H, Martin T, Wynshaw B, et al. Active anaphylaxis in IgE-deficient mice. Nature 1994; 370:367-370.
57. Takeda K, Hamelmann E, Joetham A, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997; 186:449-454.
58. Hamelmann E, Cieslewicz G, Schwarze J, et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 1999; 160:934-941.